Short, intense bouts of physical activity during daily life were associated with a lower risk of major adverse cardiovascular ...

Deprescribing antihypertensive medication is not associated with the risk for hospitalization for myocardial infarction (MI) ...

Research on hormone therapy reveals critical insights into cardiovascular disease risks, guiding clinicians in selecting ...

Risk for all-cause mortality and MACEs are affected by calcified and low-attenuation plaque burdens in patients with chronic kidney disease.

Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

The risk for recurrent cardiovascular events is high among patients with r-axSpA and a history of these events, though TNF inhibitor therapy may offer protective benefits.

Financially, Verve has a market cap of $475mn, cash balance of $540mn, and a cash runway of 7-8 quarters. Find out my ...

A new study supports previous data demonstrating the superiority of prasugrel over ticagrelor in reducing the composite outcome of mortality, myocardial infarction, or stroke in patients with acute ...

Sirius Therapeutics today announced that preliminary data from its Phase 1 clinical trial of SRSD107, a next generation siRNA ...

The 2023 AABB guidelines overall favor a restrictive transfusion strategy, recommending RBC transfusion for hemoglobin <7 ...

Esperion shares were up 13% to $3.16 after the company said it has filed New Drug Submissions to Health Canada for Nexletol and Nexlizet, non-statin medications that reduce low-density lipoprotein ...

A study reveals women with hypertensive disorders of pregnancy have a higher risk of coronary artery disease and myocardial ...